Savara Pharmaceuticals

Savara Inc. is a clinical-stage biopharmaceutical company with a mission to develop and commercialize novel, best-in-class therapies for rare respiratory diseases. Its core achievement is the advancement of molgramostim, an inhaled GM-CSF, into late-stage development for autoimmune pulmonary alveolar proteinosis (aPAP), with a Marketing Authorization Application (MAA) validated by the European Medicines Agency in March 2026. The company's strategy is to become a leader in rare respiratory therapeutics by concentrating resources on high-unmet-need orphan indications, exemplified by its focused pipeline and management team with extensive rare disease and pulmonary drug development experience.

Platform for inhaled delivery of proteins, specifically recombinant human GM-CSF, to target dysfunctional alveolar macrophages and restore pulmonary surfactant homeostasis in rare lung diseases.

Molgramostim has no direct late-stage pharmacologic competitors in aPAP, positioning it for first-mover advantage. Its primary competition is the invasive standard-of-care procedure, whole lung lavage, and off-label use of subcutaneous GM-CSF.